News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,616 Results
Type
Article (40952)
Company Profile (267)
Press Release (681387)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204683)
Career Advice (2025)
Deals (35538)
Drug Delivery (113)
Drug Development (81392)
Employer Resources (173)
FDA (16419)
Job Trends (14947)
News (346430)
Policy (32733)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2571)
Accelerated approval (34)
Adcomms (24)
Allergies (148)
Alliances (49575)
ALS (173)
Alzheimer's disease (1679)
Antibody-drug conjugate (ADC) (319)
Approvals (16696)
Artificial intelligence (528)
Autoimmune disease (160)
Automation (43)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (194)
Biotechnology (174)
Bladder cancer (161)
Brain cancer (57)
Breast cancer (647)
Cancer (4898)
Cardiovascular disease (407)
Career advice (1710)
Career pathing (36)
CAR-T (284)
CDC (47)
Celiac Disease (2)
Cell therapy (751)
Cervical cancer (37)
Clinical research (69663)
Collaboration (1731)
Company closure (4)
Compensation (1181)
Complete response letters (57)
COVID-19 (2715)
CRISPR (93)
C-suite (868)
Cystic fibrosis (143)
Data (6352)
Decentralized trials (2)
Denatured (25)
Depression (136)
Diabetes (505)
Diagnostics (6717)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (257)
Drug pricing (186)
Drug shortages (28)
Duchenne muscular dystrophy (235)
Earnings (90302)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117560)
Executive appointments (985)
FDA (19592)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1487)
Gene editing (200)
Generative AI (44)
Gene therapy (600)
GLP-1 (972)
Government (4668)
Grass and pollen (6)
Guidances (384)
Healthcare (18883)
HIV (62)
Huntington's disease (45)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (62)
Indications (124)
Infectious disease (2995)
Inflammatory bowel disease (195)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (256)
Interviews (316)
IPO (16645)
IRA (50)
Job creations (3643)
Job search strategy (1428)
JPM (57)
Kidney cancer (17)
Labor market (86)
Layoffs (547)
Leadership (32)
Legal (7951)
Liver cancer (92)
Longevity (16)
Lung cancer (661)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (815)
MASH (165)
Medical device (13784)
Medtech (13843)
Mergers & acquisitions (19971)
Metabolic disorders (1282)
mRNA (158)
Multiple sclerosis (164)
NASH (16)
Neurodegenerative disease (324)
Neuropsychiatric disorders (89)
Neuroscience (2935)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4515)
Now hiring (68)
Obesity (602)
Opinion (264)
Ovarian cancer (167)
Pain (202)
Pancreatic cancer (233)
Parkinson's disease (286)
Partnered (33)
Patents (512)
Patient recruitment (501)
Peanut (59)
People (58944)
Pharmaceutical (62)
Pharmacy benefit managers (30)
Phase 1 (21717)
Phase 2 (30659)
Phase 3 (22841)
Pipeline (5564)
Policy (290)
Postmarket research (2564)
Preclinical (9205)
Press Release (64)
Prostate cancer (248)
Psychedelics (48)
Radiopharmaceuticals (284)
Rare diseases (859)
Real estate (5956)
Recruiting (70)
Regulatory (24583)
Reports (53)
Research institute (2392)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (150)
Series A (244)
Series B (191)
Service/supplier (11)
Sickle cell disease (100)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3615)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1013)
Venture capital (89)
Weight loss (385)
Women's health (96)
Worklife (18)
Date
Today (196)
Last 7 days (745)
Last 30 days (2555)
Last 365 days (29944)
2026 (4332)
2025 (30172)
2024 (35217)
2023 (40077)
2022 (51179)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31482)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27328)
Location
Africa (736)
Alabama (85)
Alaska (7)
Arizona (312)
Arkansas (13)
Asia (39263)
Australia (6417)
California (11484)
Canada (3329)
China (1110)
Colorado (483)
Connecticut (486)
Delaware (341)
Europe (84654)
Florida (1727)
Georgia (363)
Hawaii (3)
Idaho (61)
Illinois (878)
India (70)
Indiana (532)
Iowa (22)
Japan (438)
Kansas (127)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1407)
Massachusetts (8209)
Michigan (330)
Minnesota (631)
Mississippi (5)
Missouri (129)
Montana (32)
Nebraska (28)
Nevada (124)
New Hampshire (79)
New Jersey (3046)
New Mexico (28)
New York (3022)
North Carolina (1470)
North Dakota (8)
Northern California (5628)
Ohio (341)
Oklahoma (21)
Oregon (41)
Pennsylvania (2319)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (68)
South Dakota (1)
Southern California (4477)
Tennessee (178)
Texas (1766)
United States (40672)
Utah (345)
Vermont (1)
Virginia (267)
Washington D.C. (81)
Washington State (931)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
722,616 Results for "sirnaomics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-Chemo
Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Group has published a major advancement of its novel Oligonucleotide-Chemodrug Conjugate agent.
June 13, 2024
·
4 min read
BioCapital
Sirnaomics Announces 2023 Annual Results
Sirnaomics Ltd., a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023.
March 28, 2024
·
7 min read
Business
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company
Sirnaomics Ltd. announced that the Company has established a strategic partnership with EDIRNA Inc., an early-stage biotech company focused on RNA-Editing therapeutic company, for advancing its proprietary “Edit-to-Cure Therapeutics™" platform, targeting diseases with high unmet clinical need.
July 5, 2023
·
3 min read
BioCapital
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the Company published a research article with NAR Cancer.
January 24, 2024
·
3 min read
Business
Sirnaomics Announces 2023 Interim Results
Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, has announced its interim results for the six months ended 30 June 2023.
August 30, 2023
·
10 min read
Business
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.
December 1, 2023
·
3 min read
BioCapital
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”) reported that a poster with positive clinical data of STP705 for focal fat reduction (FFR) was presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas.
November 1, 2023
·
5 min read
BioCapital
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference
Sirnaomics Ltd. will present its preclinical and clinical development of its GalAhead™ technology-based programs, focusing on an innovative dual-targeted-GalNAc design, muRNA platform drug candidates, at the upcoming 2024 OPT Congress, which took place in Boston, USA from March 13-14, 2024.
March 12, 2024
·
3 min read
BioCapital
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
Sirnaomics Ltd. hereby announces that Sirnaomics’ Senior Director of Technology Innovation, Dr. Weterings will present the latest developments on its of GalAhead™, GalNAc-RNAi therapeutic platforms and related pipeline programs at international industry conferences taking place in July.
July 12, 2023
·
2 min read
BioCapital
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024
Sirnaomics Ltd. presented the latest developments on Polypeptide Nanoparticle (PNP) platform, and its pipeline program STP705 for Focal Fat Reduction’s positive clinical data, at IMCAS World Congress 2024, which is taking place in Paris from February 1st - 3rd, 2024.
February 5, 2024
·
2 min read
1 of 72,262
Next
